This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma. Data will be collected from each patient as per routine clinical practice of the Investigator (maximum of 52 weeks, until disease progression /unacceptable toxicity or withdrawal of consent) and/or based on the local label.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Advanced and/or metastatic renal cell carcinoma
• Receiving first-line treatment with Avastin and interferon alpha-2a according to standard of care and current local label
• At least one measurable and non-measurable lesion according to RECIST criteria
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Adequate bone marrow, renal and liver function

Exclusion Criteria:

• Contraindications to Avastin and/or interferon alpha-2a as per local label

Patients with advanced and/or metastatic renal cell carcinoma treated with Avastin and interferon alpha-2a